Your browser doesn't support javascript.
loading
Cerebral aspergillosis in the era of new antifungals: The CEREALS national cohort study Nationwide CEREbral Aspergillosis Lesional study (CEREALS).
Serris, A; Benzakoun, J; Danion, F; Porcher, R; Sonneville, R; Wolff, M; Kremer, S; Letscher-Bru, V; Fekkar, A; Hekimian, G; Pourcher, V; Bougnoux, M-E; Poirée, S; Ader, F; Persat, F; Cotton, Francois; Tattevin, Pierre; Gangneux, J-P; Lelièvre, L; Cassaing, S; Bonneville, Fabrice; Houze, S; Bretagne, Stephane; Herbrecht, R; Lortholary, O; Naggara, O; Lanternier, F.
Afiliação
  • Serris A; Centre for Infectious Diseases and Tropical Medicine, Hôpital Universitaire Necker-Enfants Malades, Assistance Publique - Hôpitaux de Paris, Université de Paris, Paris, France.
  • Benzakoun J; Department of Neuroradiology, Université de Paris, INSERM UMR 1266, GHU Paris, Hôpital Sainte-Anne, DHU Neurovasc Paris Sorbonne, Paris, France.
  • Danion F; Department of Infectious Diseases, Hôpital Universitaire de Strasbourg, Université de Strasbourg, Strasbourg, France.
  • Porcher R; Clinical Epidemiology Centre, Hôpital Hôtel-Dieu, Assistance Publique Hôpitaux de Paris, and Centre of Research in Epidemiology and Statistics (CRESS), Institut National de la Santé et de la Recherche Médicale U1153; Université de Paris, Paris, France.
  • Sonneville R; Intensive Care Medicine and Infectious Diseases, Hôpital Bichat, Assistance Publique Hôpitaux de Paris, and UMR1148, LVTS, Sorbonne Paris Cité, INSERM, France.
  • Wolff M; Neurological Intensive Care Unit, Hôpital Sainte-Anne, GHU Paris Psychiatrie et NeuroSciences, Paris, France.
  • Kremer S; Department of Neuroradiology, Hôpital Universitaire de Strasbourg, Engineering science, computer science and imaging laboratory (ICube), UMR 7357, University of Strasbourg-CNRS, Strasbourg, France.
  • Letscher-Bru V; Parasitology-Mycology Laboratory, Hôpital Universitaire de Strasbourg, Strasbourg, France.
  • Fekkar A; Parasitology Mycology, hôpital Pitié-Salpêtrière, Assistance Publique Hôpitaux de Paris, Paris, France.
  • Hekimian G; Medical Intensive Care Unit, Assistance Publique-Hôpitaux de Paris, Pitié-Salpêtrière Hospital, France.
  • Pourcher V; Infectious Diseases Department, , hôpital Pitié-Salpêtrière, Assistance Publique Hôpitaux de Paris, France.
  • Bougnoux ME; Parasitology-Mycology Laboratory, Hôpital Universitaire Necker-Enfants Malades, Assistance Publique - Hôpitaux de Paris, Paris, France.
  • Poirée S; Department of adult radiology, Hôpital Universitaire Necker-Enfants Malades, Assistance Publique - Hôpitaux de Paris, Paris, France.
  • Ader F; Infectious Diseases department, Hôpital de la Croix-Rousse, Hospices Civils de Lyon, Lyon, France.
  • Persat F; Parasitology-Mycology Laboratory, Hôpital de la Croix-Rousse, Hospices Civils de Lyon, Lyon, France.
  • Cotton F; Department of Radiology, Lyon Sud Hospital, Hospices Civils de Lyon, Lyon, France; CREATIS, CNRS UMR 5220 & Inserm U1044, Université Claude Bernard Lyon 1, Villeurbanne, France.
  • Tattevin P; Infectious Diseases and Intensive Care Unit, hôpital universitaire Pontchaillou, Rennes, France.
  • Gangneux JP; Department of Mycology, Rennes University Hospital, Rennes, France.
  • Lelièvre L; Department of Infectious and Tropical Diseases, hôpital universitaire de Toulouse, France.
  • Cassaing S; Department of Parasitology Mycology, hôpital universitaire de Toulouse, Toulouse, France.
  • Bonneville F; Department of Neuroradiology, hôpital universitaire de Toulouse, Toulouse, France.
  • Houze S; Mycology Parasitology Department, hôpital Bichat, Assistance Publique Hôpitaux de Paris, Paris, France.
  • Bretagne S; Molecular Mycology Unit, National Reference Centre for Invasive Mycoses and Antifungals, UMR 2000, Institut Pasteur, CNRS, Université de Paris, Paris, France; Parasitology-Mycology Laboratory, Lariboisière, Saint-Louis, Fernand Widal Hospitals, Assistance Publique-Hôpitaux de Paris (AP-HP), Universi
  • Herbrecht R; Department of Haematology, Institut de Cancérologie de Strasbourg (ICANS), Strasbourg, France.
  • Lortholary O; Centre for Infectious Diseases and Tropical Medicine, Hôpital Universitaire Necker-Enfants Malades, Assistance Publique - Hôpitaux de Paris, Université de Paris, Paris, France; Molecular Mycology Unit, National Reference Centre for Invasive Mycoses and Antifungals, UMR 2000, Institut Pasteur, CNRS,
  • Naggara O; Department of Neuroradiology, Université de Paris, INSERM UMR 1266, GHU Paris, Hôpital Sainte-Anne, DHU Neurovasc Paris Sorbonne, Paris, France.
  • Lanternier F; Centre for Infectious Diseases and Tropical Medicine, Hôpital Universitaire Necker-Enfants Malades, Assistance Publique - Hôpitaux de Paris, Université de Paris, Paris, France; Molecular Mycology Unit, National Reference Centre for Invasive Mycoses and Antifungals, UMR 2000, Institut Pasteur, CNRS,
J Infect ; 84(2): 227-236, 2022 02.
Article em En | MEDLINE | ID: mdl-34838593
ABSTRACT

BACKGROUND:

Cerebral aspergillosis (CA) is a life-threatening disease for which diagnosis and management remain challenging. Detailed analyses from large cohorts are lacking.

METHODS:

We included 119 cases of proven (n = 54) or probable (n = 65) CA diagnosed between 2006 and 2018 at 20 French hospitals. Data were collected at baseline and during follow-up. Cerebral imaging was reviewed centrally by two neuroradiologists.

RESULTS:

The most frequent underlying conditions were hematological malignancy (40%) and solid organ transplantation (29%). Galactomannan was detected in the serum of 64% of patients. In 75% of cases, at least one of galactomannan, Aspergillus PCR, and ß-d-glucan was positive in the cerebrospinal fluid. Six-week mortality was 45%. Two distinct patterns of disease were identified according to presumed route of dissemination. Presumed haematogenous dissemination (n = 88) was associated with a higher frequency of impaired consciousness (64%), shorter time to diagnosis, the presence of multiple abscesses (70%), microangiopathy (52%), detection of serum galactomannan (69%) and Aspergillus PCR (68%), and higher six-week mortality (54%). By contrast, contiguous dissemination from the paranasal sinuses (n = 31) was associated with a higher frequency of cranial nerve palsy (65%), evidence of meningitis on cerebral imaging (83%), macrovascular lesions (61%), delayed diagnosis, and lower six-week mortality (30%). In multivariate analysis and in a risk prediction model, haematogenous dissemination, hematological malignancy and the detection of serum galactomannan were associated with higher six-week mortality.

CONCLUSION:

Distinguishing between hematogenous and contiguous dissemination patterns appears to be critical in the workup for CA, as they are associated with significant differences in clinical presentation and outcome.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Diagnostic_studies / Etiology_studies / Incidence_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Humans Idioma: En Ano de publicação: 2022 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Diagnostic_studies / Etiology_studies / Incidence_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Humans Idioma: En Ano de publicação: 2022 Tipo de documento: Article